Deals

Chai Discovery Announces Collaboration with GSK – AI Protein Folding and Design Platform to Power Drug Discovery Across GSK's Pipeline
AIChai Discovery

Chai Discovery Announces Collaboration with GSK – AI Protein Folding and Design Platform to Power Drug Discovery Across GSK’s Pipeline

Chai Discovery, the AI company building a computer-aided design suite for molecules, announced a collaboration with biopharma company GlaxoSmithKline Plc (GSK; NYSE: GSK) following a successful technology evaluation. Under the…

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension

Chengda Biotechnology Acquires Recombinant Quadrivalent Enterovirus Vaccine Technology for RMB 46 Million – Strengthening Its HFMD Vaccine Pipeline Beyond EV71

Chengda Biotechnology Acquires Recombinant Quadrivalent Enterovirus Vaccine Technology for RMB 46 Million – Strengthening Its HFMD Vaccine Pipeline Beyond EV71

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Jacobio Pharma, Oceanpine Capital and Partner Acquire Majority of Jacoray, Fuelling Early‑Stage Cardio‑Oncology R&D
BiotechHKG: 1167

Jacobio Pharma, Oceanpine Capital and Partner Acquire Majority of Jacoray, Fuelling Early‑Stage Cardio‑Oncology R&D

Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV‑13 Production and Distribution
Pharmaniaga BerhadVaccine

Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV‑13 Production and Distribution

Shandong Buchang’s Luzhou Unit Moves to Secure Exclusive Distribution of Epo‑IgG Fusion in Vietnam
Buchang PharmaceuticalsHelios Pharmaceutical

Shandong Buchang’s Luzhou Unit Moves to Secure Exclusive Distribution of Epo‑IgG Fusion in Vietnam

Laekna and Qilu Pharma Sign Exclusive China License for AKT Inhibitor LAE002 (Afuresertib)
CancerHKG: 2105

Laekna and Qilu Pharma Sign Exclusive China License for AKT Inhibitor LAE002 (Afuresertib)

Show More